In the Canary Islands, 13% of the population suffers from this pathology. This means that around 260.000 canaries suffer migraines.
Did you know that in Spain migraine affects more than 5 millions of people?
According to data from the Spanish Society of Neurology, migraine affects in Spain between an 12 and an 13% of the population.
80% of people suffering from this disease are women, generally in ages between 20 and 40 years.
This is the most prevalent neurological disease in Spain and the first cause of disability in children under 50 years. In fact, the World Health Organization (WHO) classifies migraine among the 20 most disabling diseases for humans.
The problem is that it is a difficult to diagnose disease. 75% of migraine patients take more than 2 years to obtain a diagnosis. This delay is mainly due to the fact that most patients do not go to the doctor until the pain is chronic. This also causes patients to self-medicate for long periods and receive inadequate treatment.
En Canary Islands, 13% of the population suffers from this pathology. This means that around 260.000 canaries suffer migraines.
What are the symptoms of migraine?
Migraine has a great impact on the ordinary functioning of people who suffer from it. Chronic headache, nausea, blurred vision and, in addition, other side effects like anxiety or depression, among others. On numerous occasions, these symptoms force you to abandon routine tasks, including your work activity, which has resulted in a Increase in cases of work absenteeism.
All the women have 3 times more chances of suffering migraines throughout his life than men. The reasons lie in various aspects but an important indication may be hormonal changes, stress or improper feeding.
Two very promising new alternatives finally arrive in Spain
Health has approved the financing of two new biological drugs erenumab y galcanezuma for this disorder. They act against the CGRP gene, directly related to the appearance of migraine episodes.
They are treatments thatand will be prescribed in a restricted way, that is, in patients who suffer at least 8 migraine crisis per month and who have not responded to other therapies.
The treatment integrates a novelty in its administration since it will do every 4 weeks and can be self-administered by the patient after receiving the appropriate training.
During the presentation of the drugs last Wednesday in Madrid, the head of the Headache Unit of the Clinical Hospital of Madrid Jesus Porta-Etessam, said that "This monthly administration, compared to the daily pill, is very important for the patient, since the feeling of illness is eliminated."
The results of clinical trials of both erenumab as the galcanezumab demonstrate that it is effective in reducing more than 50% of migraine days per month. In a significant percentage of patients the effectiveness reaches 70%, and there are even patients who have reached 100%.
Looking ahead, this information will allow migraine classification based on the response to drugs. In this regard, the European Medicines Agency (EMA) has authorized drugs as Preventive treatment in adults who suffer four or more days of migraine per month.
